What is the role of primaquine In maleria briefly pharmacology
Reading File
Searching the Web
primaquine malaria pharmacology mechanism of action 2024
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Excellent - I now have comprehensive, authoritative information from multiple textbooks. Here is the full answer:
Primaquine in Malaria - Pharmacology
Classification
Primaquine is an 8-aminoquinoline antimalarial drug. It is distinct from 4-aminoquinolines (like chloroquine) and is the prototype drug for targeting the liver stages of malaria parasites.
Mechanism of Action
The exact mechanism is not fully elucidated, but the current understanding is:
- Primaquine is a prodrug - it requires hepatic metabolism (via CYP2D6) to generate active hydroxylated metabolites (e.g., 5-hydroxyprimaquine)
- These metabolites act as oxidants that severely disrupt plasmodial mitochondrial function, interfering with electron transport and energy production
- In the presence of cytochrome P450 NADPH:oxidoreductase (CPR), these metabolites generate excessive H₂O₂ (reactive oxygen species), causing oxidative parasite killing
- The same oxidant mechanism also explains its toxicity (hemolysis, methemoglobinemia) in susceptible individuals
Unique Role - What Stages Does It Target?
| Stage | Activity |
|---|---|
| Primary liver schizonts (exoerythrocytic) | Yes - kills them |
| Hypnozoites (dormant liver forms of P. vivax, P. ovale) | Yes - the key indication (radical cure) |
| Gametocytes (sexual stage, all species including P. falciparum) | Yes - blocks transmission |
| Asexual blood stages (erythrocytic schizonts) | No - essentially inactive |
This is why primaquine cannot be used as monotherapy for an acute attack - it must be combined with a blood schizonticide (usually chloroquine or an ACT).
Therapeutic Uses
-
Radical cure of P. vivax and P. ovale malaria - the main indication. Chloroquine kills blood-stage parasites; primaquine eliminates hypnozoites to prevent relapse. Typical dose: 0.25 mg/kg/day for 14 days.
-
Terminal prophylaxis - given after leaving an endemic area to eliminate any residual liver-stage parasites.
-
Gametocytocidal adjunct in P. falciparum - WHO recommends a single low dose (0.25 mg/kg) alongside ACT in non-pregnant patients >6 months old to reduce mosquito transmission. At this single dose, G6PD testing is not required.
-
Causal chemoprophylaxis - limited but documented efficacy; can be used for short-duration travel to predominantly P. vivax endemic areas.
Pharmacokinetics (ADME)
| Parameter | Detail |
|---|---|
| Absorption | Near 100% oral bioavailability |
| Peak plasma level | 1-3 hours |
| Half-life | ~3-8 hours (short; requires daily dosing) |
| Distribution | Widely distributed to tissues; minimal tissue binding |
| Metabolism | Rapidly metabolized in the liver; major metabolite = carboxyprimaquine (inactive). Active oxidant metabolites formed via CYP2D6. Induces CYP1A2 |
| Excretion | Small fraction excreted unchanged in urine |
Adverse Effects
- Hemolytic anemia - the major toxicity; occurs in patients with G6PD deficiency. The oxidant metabolites exceed the capacity of G6PD-deficient red cells to maintain reduced glutathione, causing RBC lysis.
- Methemoglobinemia - can be severe in patients with NADH methemoglobin reductase deficiency; also worsened by concurrent chloroquine or dapsone.
- GI distress (nausea, abdominal cramps) - taking with food reduces this.
- Leukocytosis, mild anemia - less common at standard doses.
- Agranulocytosis/granulocytopenia - rare.
Key Contraindications
- G6PD deficiency - screen before use (except for the single low-dose gametocytocidal indication)
- Pregnancy - contraindicated
- Rheumatoid arthritis / SLE (per Lippincott)
- Infants <6 months (G6PD testing unreliable)
Resistance
Some strains of P. vivax show relative resistance to primaquine (particularly in Southeast Asia, Oceania), requiring higher or repeated doses to eliminate hypnozoites.
Summary - The "Primaquine Niche"
Primaquine fills a unique gap: it is the only widely available drug that eliminates dormant hypnozoites (preventing relapse) and has gametocytocidal activity (blocking transmission). Its newer analogue tafenoquine (FDA approved 2018) shares the same mechanism with the advantage of a single-dose regimen but the same G6PD safety concern.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, pp. 1320-1322 | Katzung's Basic & Clinical Pharmacology, 16th Ed., p. 1441 | Lippincott Illustrated Reviews: Pharmacology, p. 1169
This is a shared conversation. Sign in to Orris to start your own chat.